Nxera Pharma Co., Ltd. has achieved a second R&D milestone in its collaboration with AbbVie, resulting in a payment of US$10 million. This milestone is related to the discovery of ‘hit’ molecules against a neurology target. The agreement allows Nxera to receive up to US$40 million in research milestones and up to US$1.2 billion in potential option, development, and commercial milestones, plus royalties. Dr. Matt Barnes, Chief Scientific Officer, highlighted the progress and productivity of the collaboration. The milestone payment will be reflected in the third quarter of 2025.

Nxera Pharma is focused on developing specialty medicines for unmet needs globally, with an extensive pipeline of over 30 active programs. The company employs approximately 400 people across key locations and is listed on the Tokyo Stock Exchange. For more information, visit their website or social media channels. The press release also contains forward-looking statements about the company’s future prospects and risks involved.

Read more at GlobeNewswire: Nxera Pharma to Receive US$10 Million Milestone Payment